TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Price, Quote, News and Overview
NASDAQ:TRIB - Nasdaq - US8964385046 - ADR - Currency: USD
TRIB Quote, Performance and Key Statistics
0.731
-0.02 (-2.91%)
The current stock price of TRIB is 0.731 USD. In the past month the price decreased by -20.97%. In the past year, price decreased by -66%.
TRIB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 29.55 | 239.37B | ||
| ISRG | INTUITIVE SURGICAL INC | 78.19 | 204.42B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.35 | 152.97B | ||
| SYK | STRYKER CORP | 31.68 | 147.22B | ||
| MDT | MEDTRONIC PLC | 17.23 | 118.00B | ||
| BDX | BECTON DICKINSON AND CO | 16.21 | 64.76B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.34 | 42.24B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.45 | 39.91B | ||
| IDXX | IDEXX LABORATORIES INC | 38.85 | 35.79B | ||
| DXCM | DEXCOM INC | 53.56 | 34.52B | ||
| RMD | RESMED INC | 26.42 | 34.30B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.95 | 24.47B |
Related stock screener links
About TRIB
Company Profile
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. The company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The firm sells its products direct in the United States and through a network of international distributors.
Company Info
TRINITY BIOTECH PLC-SPON ADR
Ida Business Park, Bray, Co Wicklow
DUBLIN WICKLOW IE
CEO: Ronan O'Caoimh
Employees: 380
Company Website: https://www.trinitybiotech.com/
Investor Relations: http://www.trinitybiotech.com/investor-relations/
Phone: 1135312955111
TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ
What is the stock price of TRINITY BIOTECH PLC-SPON ADR today?
The current stock price of TRIB is 0.731 USD. The price decreased by -2.91% in the last trading session.
What is the ticker symbol for TRINITY BIOTECH PLC-SPON ADR stock?
The exchange symbol of TRINITY BIOTECH PLC-SPON ADR is TRIB and it is listed on the Nasdaq exchange.
On which exchange is TRIB stock listed?
TRIB stock is listed on the Nasdaq exchange.
What is TRINITY BIOTECH PLC-SPON ADR worth?
TRINITY BIOTECH PLC-SPON ADR (TRIB) has a market capitalization of 20.12M USD. This makes TRIB a Nano Cap stock.
How many employees does TRINITY BIOTECH PLC-SPON ADR have?
TRINITY BIOTECH PLC-SPON ADR (TRIB) currently has 380 employees.
What are the support and resistance levels for TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?
TRINITY BIOTECH PLC-SPON ADR (TRIB) has a resistance level at 0.77. Check the full technical report for a detailed analysis of TRIB support and resistance levels.
Is TRINITY BIOTECH PLC-SPON ADR (TRIB) expected to grow?
The Revenue of TRINITY BIOTECH PLC-SPON ADR (TRIB) is expected to grow by 6.69% in the next year. Check the estimates tab for more information on the TRIB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TRIB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TRIB, evaluating the profitability, health, valuation and growth aspects
- TRINITY BIOTECH PLC-SPON ADR (TRIB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TRINITY BIOTECH PLC-SPON ADR (TRIB) Sales and EPS estimates to see what analysts future expectations are.
- TRINITY BIOTECH PLC-SPON ADR (TRIB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TRINITY BIOTECH PLC-SPON ADR (TRIB) Insider and Institutional Ownership to learn about the owners and their transactions.
- TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Chart to make your own analysis
- TRINITY BIOTECH PLC-SPON ADR (TRIB) Latest news and press-releases to stay up to date.
Does TRINITY BIOTECH PLC-SPON ADR (TRIB) stock pay dividends?
TRIB does not pay a dividend.
What is the Price/Earnings (PE) ratio of TRINITY BIOTECH PLC-SPON ADR (TRIB)?
TRINITY BIOTECH PLC-SPON ADR (TRIB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.9).
What is the Short Interest ratio of TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?
The outstanding short interest for TRINITY BIOTECH PLC-SPON ADR (TRIB) is 11.17% of its float. Check the ownership tab for more information on the TRIB short interest.
TRIB Technical Analysis
TRIB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TRIB. TRIB may be in some trouble as it scores bad on both profitability and health.
TRIB Financial Highlights
Over the last trailing twelve months TRIB reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 34.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TRIB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to TRIB. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -194.92% and a revenue growth 6.69% for TRIB